Skip to content
OpenCapital
Get started

Myriad Genetics MYGN Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number at other companies

NeoGenomics logo
NeoGenomicsNEO
——
Guardant Health logo
Guardant HealthGH
——
Natera, Inc. logo
Natera, Inc.NTRA
——
BillionToOne, Inc. logo
BillionToOne, Inc. BLLN
——
Castle Biosciences logo
Castle BiosciencesCSTL
——

Other financials

Income statement

See full
Revenue$200.4M+2.3%
Gross profit$137.6M+2.5%
Operating income-$30.7M-5.9%
Net income-$34.1M-34,000%
EPS (diluted)-$0.36—

Balance sheet

See full
Cash & equivalents$126.0M+24.8%
Total debt$211.5M+34.2%
Total equity$337.4M-52.1%
Total assets$673.7M-33.0%

Cash flow

See full
Operating cash flow-$15.7M+3.7%
CapEx$18.8M+181%
Free cash flow-$19.7M+65.1%

Valuation

See full
Market cap$512.85M+13.1%
Enterprise value$598.35M+17.3%
P/S0.6×+0.1×

Profitability

See full
Gross margin70%0.0pp
Operating margin-46.9%-88.3pp
Net margin-48.2%-72.9pp
FCF margin-17%—

Returns & leverage

See full
Return on equity-76.7%-98.4pp
Debt / equity0.6×+0.4×
Current ratio2.4×+0.5×

Where this comes from

Reported directly by Myriad Genetics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.

The official record: Myriad Genetics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Myriad Genetics's share-based compensation arrangement by share-based payment award, options, outstanding, number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Myriad Genetics's share-based compensation arrangement by share-based payment award, options, outstanding, number?
Myriad Genetics (MYGN) reported share-based compensation arrangement by share-based payment award, options, outstanding, number of $700K in Q1 2026.
How has Myriad Genetics's share-based compensation arrangement by share-based payment award, options, outstanding, number changed year-over-year?
Myriad Genetics's share-based compensation arrangement by share-based payment award, options, outstanding, number decreased by 0.0% year-over-year, from $700K to $700K.
What is the long-term trend for Myriad Genetics's share-based compensation arrangement by share-based payment award, options, outstanding, number?
Over 5 years (2020 to 2025), Myriad Genetics's share-based compensation arrangement by share-based payment award, options, outstanding, number has grown at a -33.0% compound annual growth rate (CAGR), from $5.2M to $700K.